Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A; Translational Breast Cancer Research Consortium (TBCRC). Vaklavas C, et al. Among authors: lobuglio af. Breast Cancer Res. 2020 Feb 18;22(1):22. doi: 10.1186/s13058-020-01258-x. Breast Cancer Res. 2020. PMID: 32070401 Free PMC article. Clinical Trial.
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.
Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF. Forero-Torres A, et al. Among authors: lobuglio af. Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035. Clin Breast Cancer. 2010. PMID: 20705559 Free PMC article. Clinical Trial.
Recurrent read-through fusion transcripts in breast cancer.
Varley KE, Gertz J, Roberts BS, Davis NS, Bowling KM, Kirby MK, Nesmith AS, Oliver PG, Grizzle WE, Forero A, Buchsbaum DJ, LoBuglio AF, Myers RM. Varley KE, et al. Among authors: lobuglio af. Breast Cancer Res Treat. 2014 Jul;146(2):287-97. doi: 10.1007/s10549-014-3019-2. Epub 2014 Jun 15. Breast Cancer Res Treat. 2014. PMID: 24929677 Free PMC article.
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.
Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE. Forero A, et al. Among authors: lobuglio af. Cancer Immunol Res. 2016 May;4(5):390-9. doi: 10.1158/2326-6066.CIR-15-0243. Epub 2016 Mar 15. Cancer Immunol Res. 2016. PMID: 26980599 Free PMC article.
Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
Oliver PG, LoBuglio AF, Zhou T, Forero A, Kim H, Zinn KR, Zhai G, Li Y, Lee CH, Buchsbaum DJ. Oliver PG, et al. Among authors: lobuglio af. Breast Cancer Res Treat. 2012 Jun;133(2):417-26. doi: 10.1007/s10549-011-1755-0. Epub 2011 Sep 7. Breast Cancer Res Treat. 2012. PMID: 21901385 Free PMC article.
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.
Londoño-Joshi AI, Oliver PG, Li Y, Lee CH, Forero-Torres A, LoBuglio AF, Buchsbaum DJ. Londoño-Joshi AI, et al. Among authors: lobuglio af. Breast Cancer Res Treat. 2012 Jun;133(2):437-45. doi: 10.1007/s10549-011-1763-0. Epub 2011 Sep 14. Breast Cancer Res Treat. 2012. PMID: 21915634 Free PMC article.
Monoclonal antibody therapy of cancer.
LoBuglio AF, Saleh MN. LoBuglio AF, et al. Crit Rev Oncol Hematol. 1992 Nov;13(3):271-82. doi: 10.1016/1040-8428(92)90093-6. Crit Rev Oncol Hematol. 1992. PMID: 1476656 Clinical Trial. No abstract available.
230 results